Palvella Therapeutics Inc.
PVLA | NASDAQ
$158.85
+$5.44 (+3.55%)
Sep 22, 2026, 11:58 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | 25.9M | 31.42M |
Cost of Revenue | n/a | n/a | n/a | 2.78M | 2.37M |
Gross Profit | n/a | n/a | n/a | 23.12M | 29.05M |
Operating Income | -38.6M | -14.1M | -11.87M | -43.47M | -51.83M |
Interest Income | 2.59M | 642K | 6.27M | 721K | 4K |
Pretax Income | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M |
Net Income | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M |
Selling & General & Admin | 15.76M | 5.94M | 3.08M | 16.38M | 16.68M |
Research & Development | 22.84M | 8.15M | 8.79M | 50.21M | 64.2M |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 38.6M | 14.1M | 11.87M | 66.6M | 80.88M |
Interest Expense | 5.82M | 4.32M | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 38.6M | 14.1M | 11.87M | 69.38M | 83.25M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 11.25M | 2.23M | 1.27M | 930.35K | 806.84K |
Shares Outstanding (Diluted) | 11.25M | 2.23M | 1.27M | 930.35K | 806.84K |
EPS (Basic) | -3.71 | -7.83 | 14.74 | -29.61 | -56.69 |
EPS (Diluted) | -3.71 | -7.83 | 14.74 | -29.61 | -56.69 |
EBITDA | -35.9M | -13.12M | 18.69M | -30.5M | -43.37M |
EBIT | -35.9M | -13.12M | 18.69M | -33.28M | -45.74M |
Depreciation & Amortization | n/a | n/a | n/a | 2.78M | 2.37M |
Add to Watchlist
Select watchlists to add or remove PVLA